Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

比克恩丙诺

Report date: 2026/02/10 20:00:22

Base Information

Drug NameBictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate
Drug Alias Name比克恩丙诺bictegravir emtricitabine and tenofovir alafenamideBictegravir/Emtricitabine/Tenofovir AlafenamideBiktarvy必妥维
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHIV integrase inhibitorsReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseHIV integraseReverse transcriptase
Therapy Area/IndicationsHepatitis BHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2018/02/07
Country/TerritoryBelgiumCanadaUnited States +[26] 
CombinationsYes EmtricitabineTenofovir Alafenamide FumarateBictegravir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland UcGilead Sciences Shanghai Pharmaceutical Technology Co Ltd
Inactive CompaniesThe Brigham and Women's Hospital
Active IndicationsHepatitis BHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR
Related LinksN/A